Our Mission
Empower people to navigate their brain health through early testing.
Our Goals
We believe navigation of brain health is the new frontier in medical science—one that brings a significant impact in a fast-growing aging world population.
Prevention is the secret to health and wellness. Our breakthrough technology enables individuals to track the biomarkers associated with Alzheimer’s and Parkinson’s. We want to empower people with personal biometrics to make informed choices early for preventive brain care.
Team Amprion strives to deepen, enrich, and expand drug research to find the cures for Alzheimer’s and Parkinson’s through scientific advances.
Our Story
Prions are the bad actors that drive many yet incurable diseases. Cracking the code on prions is the key to cure the incurables. Alzheimer’s and Parkinson’s are our top priorities. Here’re some key milestones of our evolving journey…
Once Upon A Time
Neuroscientist Claudio Soto teams up with molecular pathologist Dr. Russ Lebovitz to cofound Amprion. Their mission: to help detect and eliminate Madcow Disease, aka Creutzfeldt-Jakob disease (CJD). Dr. Soto began developing a test assay to detect the prions, aka misfolded proteins, the bad actors driving CJD.
The Pivot
Luckily for the humans, Madcow disease dissipates. The Company pivots as the scientists pondered on a fateful question: What if there was a parallel between the misfolded proteins in Madcow disease and the brains of patients with Alzheimer’s, Parkinson’s, or other neurodegenerative disorders?
An Aha Moment!
An “Aha!” moment arrives when Dr. Soto proves in his lab that there is indeed a similarity and develops a molecular technology to detect the misfolded protein, Abeta, a biomarker found in most Alzheimer’s patients.
Amprion Was Born!
The Company expanded on Dr. Soto’s technology to detect other misfolded proteins, including Synuclein and Tau. Both types of prions are found in Parkinson’s and Alzheimer’s patients.
Our Mission
Amprion embarks on a new mission: To provide clinical tests for doctors to accurately diagnose Alzheimer’s, Parkinson’s, and ParkinZheimer spectrum diseases.
Our Science
Amprion builds an R&D lab, further enhancing its proprietary Prion Testing TechnologySM.
Scientists at work
Team Amprion establishes a new clinical laboratory, a state-of-the-art diagnostics lab, run by a full stack of talented scientists, experts, and professionals, not to mention advanced robotics when the humans are off the clock.
FDA Breakthrough Designation
The US FDA awards Amprion Breakthrough Device Designation to detect misfolded Synuclein, a biomarker for Parkinson’s. We (and our robots) cheer!
Breakthrough Publishing
Dr. Soto publishes a landmark article in Nature, bolstering the Company’s Prion Testing Technology in distinguishing between different misfolded Synuclein structures related to Parkinson’s and Multiple System Atrophy (MSA).
Push Cure Thru Covid!
Team Amprion, wearing masks and standing 6-feet apart, worked through the Covid-pandemic. The team reaches a significant milestone—meeting all approval requirements for CLIA, preparing Amprion to market various clinical tests for Alzheimer’s and Parkinson’s diagnosis.
Test For Parkinson's & LBD
We’re gearing up for the commercial launch of our first biomarker test to diagnose Parkinson’s, Lewy Body Dementia (LBD), by detecting misfolded Synuclein via CSF. Testing will be available by Q2 2021.
